论文部分内容阅读
目的:探讨肿瘤标记物CEA、CA19-9在宫颈癌治疗及预后评价中的价值。方法:选取2008年2月～2011年8月60例宫颈癌患者、40例宫颈上皮内瘤变(CIN)患者、40例同期进行体检的健康妇女为研究对象,测定三组患者血清中癌胚抗原(CEA)、糖抗原(CA19-9)的含量,并根据临床分期、组织学分级、病理类型将宫颈癌患者进行分组,比较各组CEA、CA19-9的阳性率,并测定宫颈癌患者治疗后的CEA、CA19-9含量。结果:宫颈癌患者的CEA、CA19-9含量显著高于CIN组和对照组(P<0.05)。宫颈癌的临床分期越晚、分化程度越低,CEA、CA19-9的含量越高。腺癌中CEA、CA19-9的阳性率要显著高于鳞癌(P<0.05)。经治疗后宫颈癌的CEA、CA19-9含量均较治疗前显著降低(P<0.05)。结论:CEA、CA19-9对宫颈癌的辅助诊断,组织学分型有较高的检测价值,可作为评价疗效及预后的有效指标。
Objective: To investigate the value of tumor markers CEA and CA19-9 in the treatment and prognosis of cervical cancer. Methods: From February 2008 to August 2011, 60 patients with cervical cancer, 40 patients with cervical intraepithelial neoplasia (CIN) and 40 healthy women who underwent physical examination in the same period were enrolled in this study. Serum carcinoembryonic (CEA) and carbohydrate antigen (CA19-9) in patients with cervical cancer. The patients with cervical cancer were divided into groups according to clinical stage, histological grade and pathological type. The positive rates of CEA and CA19-9 in each group were compared. After treatment CEA, CA19-9 content. Results: The content of CEA and CA19-9 in cervical cancer patients was significantly higher than that in CIN and control groups (P <0.05). The later the clinical stage of cervical cancer, the lower the degree of differentiation, the higher CEA, CA19-9 levels. The positive rates of CEA and CA19-9 in adenocarcinoma were significantly higher than those in squamous cell carcinoma (P <0.05). After treatment, the CEA and CA19-9 levels of cervical cancer were significantly lower than those before treatment (P <0.05). Conclusion: CEA and CA19-9 have high diagnostic value in diagnosis of cervical cancer and histological classification, which can be used as an effective index to evaluate curative effect and prognosis.